Martin A F, Bhatti S, Paul R J
Department of Physiology and Biophysics, University of Illinois at Chicago 60612, USA.
Comp Biochem Physiol B Biochem Mol Biol. 1997 May;117(1):3-11. doi: 10.1016/s0305-0491(96)00308-2.
Two myosin heavy chain isoforms expressed in smooth muscle, SM1 (204 kDa) and SM2 (200 kDa), are derived from alternate splicing that results in different amino acid sequences at their non-helical C-terminal tail regions. These isoforms are developmentally regulated and differentially expressed in various smooth muscle tissues. The functional role of myosin isoforms differing at the C-terminal tail has been investigated both in vitro and in vivo. Removal of the C-terminal tail of SM1 by chymotrypsin activates the ATPase of myosin at low Mg2+ but does not change the maximum activity. Addition of peptides, mimicking C-terminal tail regions specific to the SM1 and SM2 isoforms, to permeabilized taenia coli smooth muscle fibers inhibits maximum shortening velocity (Vm) and decreases Ca2+ sensitivity but has no effect on maximum force. The inhibition of Vm by the SM1-peptide was not reversed on washout, whereas Vm inhibition by the SM2-peptide is reversible. We demonstrated that the SM1 peptide specifically bound to myosin at the subfragment 2-light meromyosin (S2-LMM) junction using crosslinking and immunomicroscopy. Modification at this site could have a direct effect on crossbridge function. The relation between C-terminal myosin isoforms and contractile function in vivo was examined using estrogen administration to ovariectomized rats to increase the relative expression of the SM1 C-terminal isoform in uterine smooth muscle. This increase in SM1 was significantly correlated with an increase in Vm. In contrast, the high ATPase N-terminal isoform was decreased by administration of estrogen to ovariectomized rats. Thus, changes in C-terminal isoform distribution appear to affect contractile function in vivo. We propose a mechanism whereby the interactions between the C-terminal tail of one myosin molecule and the S2-LMM region of another in the thick filament can modulate contractility in an isoform specific manner. Further work is needed to unequivocally identify the function of smooth muscle myosin isoforms. However, our evidence suggests that the C-terminal heavy chain isoforms may be important modulators of smooth muscle contractility.
在平滑肌中表达的两种肌球蛋白重链异构体,即SM1(204 kDa)和SM2(200 kDa),源自可变剪接,这导致它们在非螺旋C末端尾部区域具有不同的氨基酸序列。这些异构体在发育过程中受到调控,并在各种平滑肌组织中差异表达。已经在体外和体内研究了C末端尾部不同的肌球蛋白异构体的功能作用。用胰凝乳蛋白酶去除SM1的C末端尾部可在低Mg2+条件下激活肌球蛋白的ATP酶,但不会改变最大活性。向透化的结肠带平滑肌纤维中添加模拟SM1和SM2异构体特异性C末端尾部区域的肽,可抑制最大缩短速度(Vm)并降低Ca2+敏感性,但对最大力量没有影响。SM1肽对Vm的抑制作用在洗脱后不会逆转,而SM2肽对Vm的抑制作用是可逆的。我们使用交联和免疫显微镜技术证明,SM1肽特异性结合于肌球蛋白的亚片段2-轻酶解肌球蛋白(S2-LMM)连接处。该位点的修饰可能对横桥功能产生直接影响。通过对去卵巢大鼠施用雌激素以增加子宫平滑肌中SM1 C末端异构体的相对表达,研究了体内C末端肌球蛋白异构体与收缩功能之间的关系。SM1的这种增加与Vm的增加显著相关。相反,对去卵巢大鼠施用雌激素会降低高ATP酶N末端异构体。因此,C末端异构体分布的变化似乎会影响体内的收缩功能。我们提出了一种机制,即一条肌球蛋白分子的C末端尾部与粗肌丝中另一条肌球蛋白分子的S2-LMM区域之间的相互作用可以以异构体特异性方式调节收缩性。需要进一步的工作来明确鉴定平滑肌肌球蛋白异构体的功能。然而,我们的证据表明,C末端重链异构体可能是平滑肌收缩性的重要调节因子。